Of the completed trials related to targeting the Mcl1 protein (Table 15), S64315 has been tested as a single agent against MM and DLBCL (NCT02992483) in untreated relapsed/refractory patients to establish maximum tolerated doses and the results for which are to be published. This evidence concerns the gene MCL1 and diffuse large B-cell lymphoma.